Skip to main content
U.S. flag

An official website of the United States government

Return to Search

ICD-10 C and M Meeting Materials

Guidance for meeting materials for the procedure code issues listed by date of the scheduled meetings.

Issued by: Centers for Medicare & Medicaid Services (CMS)

Issue Date: September 14, 2020

The September 10-11, 2024 ICD-10 COORDINATION AND MAINTENANCE COMMITTEE MEETING will be fully virtual. Registration is required for attendance.

To register in advance for the webinar go to:

https://cms.zoomgov.com/webinar/register/WN_8hiZrGNcQYCFuH9P7LCloQ

After registering, you will receive a confirmation email containing information about joining the webinar.

Consistent with the requirements of section 1886(d)(5)(K)(iii) of the Social Security Act, applicants submitted requests to create a unique procedure code to describe the administration of a therapeutic agent, such as the option to create a new code in Section X within the International Classification of Diseases, 10th Revision, Procedure Coding System (ICD-10-PCS). CMS will not be presenting these new technology add-on payment (NTAP)-related ICD-10-PCS procedure code requests that involve the administration of a therapeutic agent at the upcoming virtual meeting on September 10-11, 2024. The two NTAP-related ICD-10-PCS procedure code requests that involve the administration of a therapeutic agent are:

  1. Administration of emapalumab-lzsg
  2. Administration of tarlatamab-dlle

CMS will be soliciting public comments regarding any clinical questions or coding options for the two listed procedure code topics related to NTAP-related ICD-10-PCS code requests that involve the administration of a therapeutic agent in advance of the meeting continuing through the end of the public comment period.

The deadline to submit comments for topics being considered for an April 1, 2025 implementation is October 11, 2024 and the deadline to submit comments for topics being considered for an October 1, 2025 implementation is November 13, 2024. Members of the public should send any questions or comments to the CMS mailbox at: ICDProcedureCodeRequest@cms.hhs.gov by the designated deadline.

Prior to the meeting, CMS will post a question and answer document to address clinical or coding questions that members of the public have submitted related to the two therapeutic agents. At a later date, CMS will post an updated question and answer document to address any additional clinical or coding questions that members of the public may have submitted by the designated deadlines.

CMS will present the NTAP-related ICD-10-PCS procedure code requests that do not involve the administration of a therapeutic agent and all non-NTAP-related procedure code requests during the virtual meeting on September 10, 2024, consistent with the standard meeting process.

CMS will make all meeting materials and related documents available below. Any inquiries related to the procedure code topics scheduled for the September 10-11, 2024 ICD-10 Coordination and Maintenance Committee meeting that are under consideration for an April 1, 2025 or an October 1, 2025 implementation should be sent to the CMS mailbox at: ICDProcedureCodeRequest@cms.hhs.gov by the designated deadline.


Below are the meeting materials for the procedure code issues listed by date of the scheduled meetings. These materials include the Agenda and Materials, as well as any slides or other files made available.

Presentations for procedure code requests are conducted by both the requestor and CMS during the C&M meeting. Discussion from the requestor generally focuses on the clinical issues for the procedure or technology, followed by the proposed coding options from a CMS analyst. Topics presented may also include requests for new procedure codes that relate to a new technology add-on payment (NTAP) request.

HHS is committed to making its websites and documents accessible to the widest possible audience, including individuals with disabilities. We are in the process of retroactively making some documents accessible. If you need assistance accessing an accessible version of this document, please reach out to the guidance@hhs.gov.

DISCLAIMER: The contents of this database lack the force and effect of law, except as authorized by law (including Medicare Advantage Rate Announcements and Advance Notices) or as specifically incorporated into a contract. The Department may not cite, use, or rely on any guidance that is not posted on the guidance repository, except to establish historical facts.